A recent propensity-matched study comparing radical surgery versus focal therapy (mostly Sonacare's Sonablate HIFU treatment) shows the quality of life benefits of minimally invasive prostate cancer treatment!
On Dec. 20, 2015, Stephen Scionti, M.D., medical director of Vituro Health and founder of the Scionti Prostate Center in Sarasota, Fla., spoke with cancertherapyadvisor.com about the recently FDA-cleared HIFU technology and the importance of patients only receiving the treatment from physicians highly trained with HIFU.
On Dec. 8, 2015, Vituro Health Medical Director Stephen Scionti, M.D., caught up with ABC 7 in Sarasota, Fla., to discuss HIFU therapy.
The presence of prostate cancer can be signaled by an elevated prostate-specific antigen (PSA) level, a test result which can be alarming to any patient and confirmed by a prostate biopsy. Vituro Health, a comprehensive prostate care provider that empowers men during all stages of life, has launched operations to offer complete prostate management services, including minimally-invasive high intensity focused ultrasound (HIFU) therapy. Until now, HIFU has only been available to patients internationally.
